KMPH KemPharm
- 5.810
- 0.0000.00%
KemPharm News
10-Q: Quarterly report
StockNews.com Initiates Coverage on Zevra Therapeutics (NASDAQ:KMPH)
Equities research analysts at StockNews.com began coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report issued on Sunday. The firm set a "hold" rating on the special
Zevra Therapeutics (NASDAQ:KMPH) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a report published on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical comp
Zevra Therapeutics (NASDAQ:KMPH) Receives New Coverage From Analysts at StockNews.com
Equities research analysts at StockNews.com assumed coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a
Zevra Therapeutics, Inc. (NASDAQ:KMPH) Short Interest Down 5.5% in February
Zevra Therapeutics, Inc. (NASDAQ:KMPH – Get Rating) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,370,000 shares, a dec
Zevra Therapeutics (KMPH) Set to Announce Quarterly Earnings on Tuesday
Zevra Therapeutics (NASDAQ:KMPH – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, March 7th. Analysts expect the company to announce earnings of ($0.
Zevra Therapeutics Starts Trading Under ZVRA Ticker Symbol on Nasdaq
10:54 AM EST, 03/01/2023 (MT Newswires) -- Zevra Therapeutics (ZVRA), previously known as KemPharm (KMPH), said it will start trading Wednesday under its new ticker symbol ZVRA on the Nasdaq Global Se
Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023New Company name, Zevra, is Greek for zebra, the internatio
Verve Therapeutics (NASDAQ:VERV) Vs. KemPharm (NASDAQ:KMPH) Head-To-Head Review
KemPharm (NASDAQ:KMPH – Get Rating) and Verve Therapeutics (NASDAQ:VERV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will
Zevra Therapeutics Says Arimoclomol Research Featured In Two Poster Presentations At 19th Annual WORLDSymposium 2023
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC)
KemPharm Changes Name To Zevra Therapeutics, Inc.; To Trade On Nasdaq Under New Ticker Symbol "ZVRA" Starting March 1, 2023
KemPharm Changes Name To Zevra Therapeutics, Inc.; To Trade On Nasdaq Under New Ticker Symbol "ZVRA" Starting March 1, 2023
Short Interest in KemPharm, Inc. (NASDAQ:KMPH) Expands By 5.8%
KemPharm, Inc. (NASDAQ:KMPH – Get Rating) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,450,000 shares, a gr
KemPharm Enhances Senior Management Team
Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc.
KemPharm, Inc. (NASDAQ:KMPH) Sees Significant Growth in Short Interest
KemPharm, Inc. (NASDAQ:KMPH – Get Rating) was the target of a significant increase in short interest during the month of December. As of December 30th, there was short interest totalling 1,630,000 sh
KemPharm (NASDAQ:KMPH) Shares Pass Above Fifty Day Moving Average of $4.75
Shares of KemPharm, Inc. (NASDAQ:KMPH – Get Rating) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $4.75 and traded as high as $6.29
Express News | KemPharm Announces Promotion of Sven Guenther to Chief Scientific Officer, Christal Mickle to Chief Pdt Development Officer >KMPH
KemPharm Appoints Matthew Plooster as Chair, Richard Pascoe as CEO
07:13 AM EST, 01/09/2023 (MT Newswires) -- KemPharm (KMPH) said Monday has appointed Matthew R. Plooster as board chair, effective immediately. Plooster had been an independent director. Meanwhile, Ex
KemPharm Announces Matthew R. Plooster Named Chairman Of The Board Of Directors And Richard W. Pascoe Appointed Chief Executive Officer
KemPharm Announces Matthew R. Plooster Named Chairman Of The Board Of Directors And Richard W. Pascoe Appointed Chief Executive Officer
Express News | KemPharm Names Richard Pascoe CEO >KMPH
Analysis
Price Target
No Data
